Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

29452 ARTÍCULOS , VIENDO DEL 346 AL 360

Neuroinflammatory and molecular pathways in Alzheimer's disease: mechanistic crosstalk and emerging therapeutic opportunities

Thakur A, Sharma R, Kumari S, Prakash D, Devi A.

Inflammopharmacology. 2026 Sep;34(9):6059-6088. doi: 10.1007/s10787-026-02371-7. Epub 2026 Aug 19.

Microglial immunometabolic reprogramming in Alzheimer's disease: From mitochondrial dysfunction and redox imbalance to NLRP3 inflammasome-driven neuroinflammation

Li S, Jin J, Liu Y, Yuan J, Dong Y, Wang Z, Li L, Zhang Y.

J Alzheimers Dis. 2026 Sep;113(2):489-500. doi: 10.1177/13872877261469862. Epub 2026 Jul 31.

Targeting microglia: A new strategy for the treatment of Alzheimer's disease

Zheng M, Yang M, Su W, Tian L, Gao W.

J Neuroimmunol. 2026 Sep;418:578966. doi: 10.1016/j.jneuroim.2026.578966. Epub 2026 May 14.

Covalent small-molecule RNA targeting in Alzheimer's disease: Computational strategies, challenges and opportunities

Kumar V, Arulsamy S, Sharma S, Kumar S, Kakoty V.

Drug Discov Today. 2026 Sep;31(5):104758. doi: 10.1016/j.drudis.2026.104758. Epub 2026 Aug 4.

Aluminum and Alzheimer's disease in the 21st century: An umbrella review of evidence and controversies

Domingo JL, Colomina MT.

Neurotoxicology. 2026 Sep;116:103531. doi: 10.1016/j.neuro.2026.103531. Epub 2026 Jul 24.

Temporal trends in the prevalence of Alzheimer's disease, 1980-2024: a systematic review and meta-analysis

Hu M, Sun Z, Mao D, Tian X, Shang Q.

Front Public Health. 2026 Aug 19;14:1884058. doi: 10.3389/fpubh.2026.1884058. eCollection 2026.

Frailty as an underrepresented dimension in clinical trials of Alzheimer's disease therapies

Solfrizzi V, Imbimbo BP.

J Alzheimers Dis. 2026 Sep;113(1):83-88. doi: 10.1177/13872877261466693. Epub 2026 Jul 9.

Characterising patients with Alzheimer's disease in England: a cohort study using data from Clinical Practice Research Datalink linked to Hospital Episode Statistics

Afonso AS, Schroeder KM, Mitchell L, Carragher N, Casey C, Patel N.

BMJ Open. 2026 Aug 28;16(8):e115438. doi: 10.1136/bmjopen-2025-115438.

Alzheimer's disease subtyping approaches and the role of co-pathologies

Gawor K, Statz K, Schaeverbeke J, Thal DR.

Brain. 2026 Sep 7;149(9):2936-2954. doi: 10.1093/brain/awag157.

Comparative risk of amyloid-related imaging abnormalities with anti-amyloid-β monoclonal antibodies: A systematic review and penalized likelihood network meta-analysis of randomized trials

Sharma A, Suresh V, Kola PR, Raj R, Javairia F, Nithyanandam A, Kaur A, Arora H, Uwishema O, Gorty D, Beriwal N, Verma A, Qidwai K, Singh Malhotra H, Kumar Garg R.

J Alzheimers Dis. 2026 Sep;113(1):65-82. doi: 10.1177/13872877261466097. Epub 2026 Jul 11.

Chronic schizophrenia versus Alzheimer's disease: neuroimaging perspectives on the late-life course of schizophrenia

Noroozian M, Givian H, Vafaee MS.

J Neural Transm (Vienna). 2026 Aug;133(8):1953-1962. doi: 10.1007/s00702-026-03230-z. Epub 2026 Jul 23.

Passive Digital Marker-enabled identification and engagement for Alzheimer's disease and related dementias care in primary care: the INCLUDE study protocol

Summanwar D, Lee L, Willis DR, Ben Miled Z, Baucco C, Webber ECC, Perkins AJ, Powell AY, Fowler NR.

BMJ Open. 2026 Sep 8;16(9):e116755. doi: 10.1136/bmjopen-2026-116755.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias